What do systematic reviews say?

Pulse vs continuous dexamethasone therapy

Pulse may leads to higher death or bronchopulmonary dysplasia at 36 weeks' PMA compared with continuous dexamethasone therapy (low certainty).

• Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants 2023 · Cochrane Headline outcomes only
  RR 1.38 [1.02, 1.88]
  2 studies · 197 participants
  Low

Pulse vs continuous dexamethasone therapy

It is very uncertain whether pulse changes death or abnormal neurodevelopmental outcome (various definitions) compared with continuous dexamethasone therapy (very low certainty).

• Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants 2023 · Cochrane Headline outcomes only
  RR 1.23 [0.79, 1.92]
  1 study · 76 participants
  Very low

Intervention not reported

The review found no eligible studies for this question.

• Pulse oximetry screening for critical congenital heart defects 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Pulse oximetry screening for critical congenital heart defects 2018 · Cochrane Headline outcomes only
  no estimate extracted
  19 studies · 436758 participants
  Low